Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05072990
Other study ID # 2020-035-KY
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 27, 2021
Est. completion date May 15, 2022

Study information

Verified date September 2023
Source Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is a retrospective review of participants who visited Department of Endocrinology, Guang'anmen Hospital and accepted traditional Chinese medicine formula for at least sis months, from January 2015 to December 2020. All the participants should be diagnosed as type 2 diabetes mellitus, obesity and dyslipidemia. Therapeutic effect of traditional Chinese medicine will be evaluated based on the changes of blood glucose, body mass index, blood lipids, and blood pressure.


Description:

The diagnostic criteria for type 2 diabetes mellitus and obesity are based on the Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). The diagnostic criteria of dyslipidaemia are based on the Chinese Guidelines on Prevention and Treatment of Dyslipidaemia in Adults (2016, revision edition).


Recruitment information / eligibility

Status Completed
Enrollment 95
Est. completion date May 15, 2022
Est. primary completion date April 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Meet at least three of the requirements below; 1) Fasting Plasma Glucose > 6.1 mmol/L or 2-hour Postprandial Blood Glucose > 7.8 mmol/L or diagnosed as type 2 diabetes mellitus; 2) Body Mass Index > 25 kg / m2; 3) Total Cholesterol > 5.2 mmol / L; Or Triglyceride > 1.70 mmol / L; Or Low-Density Lipoprotein > 3.12 mmol / L; Or High-Density Lipoprotein < 1.04 mmol/L. 4) Systolic blood pressure > 130 mmHg or Diastolic blood pressure > 85 mmHg or diagnosed as hypertension; 2. Received 6 months of continuous Chinese herbal medicine treatment; 3. During the period of receiving Chinese herbal medicine, the patients continued to take western medicine according to the doctor's advice as before. 4. During the period of receiving Chinese herbal medicine, diet and exercise continued according to the original routine, and the tests would be reviewed in the same institution. 5. Aged 18 to 80 years at the time of their consent; 6. Signed informed consent. Exclusion Criteria: - Patients who had serious heart, lung, liver, kidney and brain diseases; serious infectious or hemorrhagic diseases; serious nervous system diseases, mental instability; or could not cooperate with treatment were excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Chinese herb medicine
Patients took 200 ml Chinese herb decoction twice a day before breakfast and dinner.

Locations

Country Name City State
China Guang'anmen Hospital, China Academy of Chinese Medical Sciences Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline HbA1c at 3 months, 6 months 0 month, 3 months, 6 months
Primary Changes from Baseline Fasting Blood Glucose at 3 months, 6 months 0 month, 3 months, 6 months
Primary Changes from Baseline Low Density Lipoprotein at 3 months, 6 months 0 month, 3 months, 6 months
Primary Changes from Baseline Triglyceride at 3 months, 6 months 0 month, 3 months, 6 months
Primary Changes from Baseline Body Mass Index at 3 months, 6 months 0 month, 3 months, 6 months
Secondary Changes from Postprandial Blood Glucose at 6 months 0 month, 6 months
Secondary Changes from Total Cholesterol at 6 months 0 month, 6 months
Secondary Changes from High Density Lipoprotein at 6 months 0 month, 6 months
Secondary Changes from Systolic Blood Pressure at 6 months 0 month, 6 months
Secondary Changes from Diastolic Blood Pressure at 6 months 0 month, 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05606471 - Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets Phase 4
Withdrawn NCT02977039 - Effect of a Plant Rich Diet on in People With Type 2 Diabetes and Obesity N/A
Recruiting NCT06223490 - Effect of Cryolipolysis on Insulin Resistance N/A
Completed NCT04363710 - Prospective Interventional Study on Reversibility of Type 2 Diabetes Mellitus With Hypocaloric Diet N/A
Recruiting NCT05277558 - Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D)
Recruiting NCT04621929 - Obesity and Uric Acid Stones Study Phase 3
Completed NCT04332354 - Glycemic Profile by CGMS in Diabetic Patients After Bariatric Surgery
Completed NCT05890950 - A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes Phase 1
Withdrawn NCT04910997 - Heart Rate Variability-Guided Exercise Training in Type 2 Diabetes N/A
Completed NCT04931836 - The Influence of Physical Activity on the Gut Microbiome of Pre-Diabetic Adults N/A
Recruiting NCT06005012 - Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM Phase 2
Terminated NCT04741074 - Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy Phase 3
Recruiting NCT05838287 - Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants Phase 4
Active, not recruiting NCT04916314 - REmote SUpport for Low-Carbohydrate Treatment of Type 2 Diabetes N/A
Completed NCT04303819 - The Effect of Exenatide on Fasting Bile Acids
Recruiting NCT05446415 - L-Cell Activity in Small Intestine as Biliopancreatic Loop in Obese Patients With DM2 Submitted to RYGBP N/A
Completed NCT05770076 - Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Type 2 Diabetes Patients (DELI_Diab Study) N/A
Active, not recruiting NCT05409027 - A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62 Phase 1
Completed NCT02937987 - Dietary Intake, Eating Behavior, Physical Activity Level and Their Relationships With Glycemic and Weight Control in Hong Kong Chinese Type 2 Diabetic Patients